Protocols

Roche will have to wait on its big MS drug application; Pfizer ties up with BioInvent on new antibodies for cancer

Roche’s pioneering MS drug Ocrevus (ocrelizumab) has hit a snag at the FDA. Billed as one of the biggest potential blockbusters in the pipeline, which may be used for both relapsing and progressive MS, the agency says it needs more time to review some new info on the manufacturing side of the application. Manufacturing has repeatedly been cited in a slate of CRLs this year, which will mark a decade low in new drug approvals.

Pfizer is stepping up with $10 million in near-term payouts to get a new immuno-oncology collaboration working with Sweden’s BioInvent. They’ll be working on antibodies that target myeloid cells. If they can advance 5 antibodies to the market – a long shot at best – Pfizer is willing to add hundreds of millions of dollars in added milestone payments.

Patrick Barry, Endo

Patrick Barry, Endo

Endo International has appointed Patrick Barry as Senior Vice President, US Branded Pharmaceuticals, effective immediately; and Matthew Davis as Senior Vice President, Research and Development Branded Pharmaceuticals, effective January 3, 2017.

 


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy





Bracket